Tier 3 — preclinical

Oral Intake and Topical Application of Hyaluronic Acid Ameliorates Skin Aging Signs: Efficacy Results of a Placebo-Controlled In&Out Trial

Vincenzo Nobile, Gloria Roveda, Eleonora Spartà, Francesco Tursi
Cosmetics 2025 12(2):52

Bibliography

DOI
10.3390/cosmetics12020052

Study snapshot

DesignMulticenter randomized placebo-controlled four-arm parallel clinical trial
Model88 multiethnic adults with skin-aging signs
Samplen=88
InterventionOral ExceptionHYAL Star 200 mg/day and/or topical PrincipHYAL Cube3 0.5%, with matched oral and topical placebos
Duration56 days
EndpointsSkin moisturization; Brightness; Smoothness; Roughness; Firmness; Elasticity; Clinical aging signs; Self-assessment

What the study showed, in plain terms

This four-arm study separately tested oral full-spectrum HA, topical full-spectrum HA, their combination, and double placebo. Oral active treatment improved several skin texture/firmness measures over time, while the combined oral+topical approach generally produced the broadest improvements. Results are product-specific and should not be treated as proof that every oral HA formulation behaves identically.

Key findings

What this study can and cannot tell us

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology